Strides Pharma Science’s arm gets USFDA approval for Potassium Chloride Oral Solution

18 Nov 2022 Evaluate

Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global has received approval for Potassium Chloride Oral Solution USP, 40 mEq/15mL (20%) from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride Oral Solution USP, 40 mEq/15 mL (20%) of Genus Lifesciences Inc.

The approval further strengthens the Potassium Chloride franchise for the company which now comprises of Extended-Release Capsules, Extended-Release Tablets, Powder for Oral Solutions and Oral Solutions. The Company also has a pipeline of other Potassium Chloride products which are expected to be approved and launched in FY24. The entire Potassium Chloride range of products for the company has a cumulative market opportunity of around $330 Mn as per IQVIA. The products will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 280 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 261 ANDAs have been approved and 19 are pending approval. The company has set a target to launch around 20 new products every year in the US.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

889.80 -12.55 (-1.39%)
01-Jan-2026 13:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.10
Dr. Reddys Lab 1250.00
Cipla 1499.50
Zydus Lifesciences 912.80
Lupin 2100.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×